CDK4 and cancer: Our data reinforce the importance of these inhibitors in cancer therapy suggesting that the inactivation of Cyclin D·Cdk4,6 not only should produce tumour regression, as expected from its role in cell proliferation, but should restrict tumour spreading and metastasis as well.